No title
SpectraCure: from university start-up to public company Johannes Swartling, CTO Lund, 5 April 2019 • Founded 2003 as a start-up from Lund University, Division of Atomic Physics • Medical device company – interstitial photodynamic therapy (PDT) • Focus on treatment of prostate cancer • Currently: phase I-II clinical trials at Princess Margret Hospital in Toronto, Canada, Pennsylvania University Hos
https://www.mlc.lu.se/fileadmin/mlc/Minnesanteckningar/SpectraCure_Johannes_Swartling.pdf - 2026-05-25
